ORIGINAL INVESTIGATION
|
|
- Maximillian Booth
- 5 years ago
- Views:
Transcription
1 ORIGINAL INVESTIGATION Comparison of N-Terminal Pro B-Natriuretic Peptide, C-Reactive Protein, and Creatinine Clearance for Prognosis in Patients With Known Coronary Heart Disease Dietrich Rothenbacher, MD, MPH; Wolfgang Koenig, MD; Hermann Brenner, MD, MPH Background: The purpose of this study was to investigate the prognostic role of N-terminal pro Bnatriuretic peptide (NT-proBNP) serum level compared with C-reactive protein (CRP) level and creatinine clearance (CrCl) for the subsequent risk of cardiovascular events in a large cohort of patients with stable coronary heart disease (CHD). Methods: Serum concentrations of NT-proBNP and CRP and CrCl were measured at baseline in a cohort of 1051 patients aged 30 to 70 years with CHD. The Cox proportional hazards model was used to determine the prognostic value of NT-proBNP, CRP, and CrCl on a combined cardiovascular disease (CVD) end point (fatal and nonfatal myocardial infarction and stroke). Results: During follow-up (mean of 48.7 months), 95 patients (9.0%) experienced a secondary CVD event. Patients in the top quartile of the NT-proBNP distribution at baseline had a hazard ratio (HR) of 3.34 (95% confidence interval [CI], ) for subsequent secondary CVD events compared with those in the bottom quartile (P for trend ) after controlling for age, sex, smoking status, history of diabetes mellitus, initial management of CHD, rehabilitation clinic, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and treatment with lipid-lowering drugs. For CRP, the corresponding HR was 1.76 (95% CI, ) (P value for trend,.06). Patients with CrCl levels lower than 60 ml/min had an HR of 2.39 (95% CI, ) compared with patients with a CrCl of 90 ml/min or higher (P for trend,.002). If all 3 markers were included simultaneously in 1 model, NT-proBNP still showed predictive ability for recurrent CVD events. Conclusion: N-terminal probnp may be a clinically useful marker weeks after an acute coronary event and may provide complementary prognostic information to established risk determinants. Arch Intern Med. 2006;166: Author Affiliations: Department of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany (Drs Rothenbacher and Brenner); and Department of Internal Medicine II Cardiology, University of Ulm Medical Center, Ulm, Germany (Dr Koenig). PREVALENCE OF CORONARY heart disease (CHD) will increase within the next years, and CHD will be the number 1 cause of disability and death by the year 2020 worldwide. 1 Therefore, beside new avenues and concepts of primary prevention, improved secondary preventive strategies of CHD are necessary to reduce the burden of disease and recurrent complications for the individual as well as for society. CME course available at The use of biological markers for diagnostic purposes and risk stratification represents one promising area in cardiology. Meanwhile convincing evidence suggests that CHD is an inflammatory process, and a variety of inflammatory markers such as C-reactive protein (CRP) may play a role in disease risk assessment. 2 In addition, renal impairment is also an independent risk factor for CHD. 3 B-type natriuretic peptide (BNP) and the N-amino terminal (NT)-proBNP (the latter with a much longer half-life than For editorial comment see page 2428 BNP 4 ) have been initially introduced as markers to aid in the diagnosis of congestive heart failure (CHF), to estimate the severity of cardiac dysfunction, and to guide the management and adjustment of pharmacotherapy. 4-7 In addition, evidence is accumulating that raised BNP and NT-proBNP plasma/serum levels are of prognostic value because they are independently associated with adverse prognosis in several cardiac disorders, including CHF and acute CHD, 5,8,9 and they may allow identifying subjects at risk for ad- 2455
2 verse cardiovascular disease (CVD) events to tailor therapy. 10 Recent studies also demonstrated their prognostic value in predicting all-cause mortality in patients with prevalent CHD Whether elevated NT-proBNP serum levels in patients with CHD reflect a specific pathomechanism of cardiac disease, which is independent from other basic concepts of atherogenesis such as vascular inflammation and renal disease, is under debate. In the present study, we investigated the prognostic role of NT-proBNP serum levels for the subsequent risk of cardiovascular events in a large cohort of patients with stable CHD weeks after the first clinical manifestation or diagnosis, after controlling for potential confounders, and compared it with the prognostic value of a serum marker of systemic inflammation (CRP) and renal function (creatinine clearance [CrCl]). METHODS STUDY POPULATION All patients with CHD (International Classification of Diseases, Ninth Revision [ICD-9] codes ) aged 30 to 70 years and participating in an in-hospital rehabilitation program between January 1999 and May 2000 in 2 cooperating clinics (Schwabenland-Klinik, Isny, and Klinik am Südpark, Bad Nauheim, Germany) were enrolled in the study, and clinically relevant CHD was defined by a greater than 50% diameter stenosis of 1 or more major epicardial coronary arteries. In Germany, every post acute coronary syndrome patient by law has the right to receive institutionalized cardiac rehabilitation in a specialized center, which is used by most patients. This in-hospital rehabilitation program after acute coronary syndrome usually begins within the first weeks after discharge from the acute care hospital. Although we recruited patients only in 2 such in-patient rehabilitation centers (one in the south of Germany and the other in the middle of Germany), these specialized centers serve a large geographic area with a radius of up to 200 km, and therefore, patients were referred from a large number of different acute care hospitals. In the present study, only patients who were admitted within 3 months after the acute event or coronary artery bypass grafting (CABG) were included. Of all eligible patients, 58% agreed to participate. The mean interval from the acute event to recruitment was 43 days (interquartile range, days). All subjects gave written informed consent. The study was approved by the ethics boards of the Universities of Ulm and Heidelberg and of the physicians chamber of the States of Baden- Württemberg and Hessen (Germany). DATA COLLECTION At the beginning of the in-hospital rehabilitation program, all participants filled out a standardized questionnaire containing sociodemographic information and medical history. In addition, information was taken from the patients hospital medical charts, which also included information from the acute care hospital. From all patients, a 12-lead electrocardiogram (ECG) was recorded at the beginning of the rehabilitation and evaluated according to a standardized protocol by a trained investigator. Intrarater (interrater) reliability was determined in 100 randomly chosen ECGs by a blinded second rating from the same investigator 4 weeks later and from an independent second investigator. The coefficients were 1 (0.88) for sinus tachycardia ( 100/min), 0.85 (1.0) for atrial flutter or fibrillation, and 0.96 (0.73) for infarction location. Information on left ventricular function (LVF) was derived from (1) the most recent left ventricular cineangiography (available in 680 patients [67%]) or (2) from echocardiographic study when available (available in 821 patients [78%]). This way, LVF could be assessed in 964 patients (91.7%). Data on LVF were collected from patients medical charts and were documented on a 4-point semiquantitative scale as normal (ejection fraction [EF], 65%), as mild depression (EF, 50%-65%), moderate depression (EF, 35%-50%), or severe depression (EF, 35%). In all patients, active follow-up was conducted 1, 3, and 4.5 years after discharge from the rehabilitation center. Information regarding secondary cardiovascular events and treatment since discharge was obtained from the primary care physician by means of a standardized questionnaire. If a patient had died during follow-up, the death certificate was obtained from the local public health department, and the main cause of death was coded according to the ICD-9. Secondary cardiovascular events were defined either as CVD as the main cause of death (as stated in the death certificate), nonfatal myocardial infarction (MI), or ischemic stroke. All nonfatal secondary events were reported by the primary care physicians. LABORATORY ANALYSIS Blood was drawn at baseline at the end of the rehabilitation phase in a fasting state under standardized conditions and stored at 80 C until analysis. N-terminal probnp was measured from plasma by means of a 1-step enzyme immunoassay based on electrochemiluminescence (Elecsys; Roche Diagnostics, Mannheim, Germany). The interassay coefficient was between 3.1% and 7.2%. C-reactive protein was determined by a highsensitivity assay (N Latex CRP mono; Dade Behring, Marburg). For measurement of creatinine, in one hospital the conventional kinetic Jaffe method (interassay coefficient of variation, 2.4%-5.7%) was used, whereas in the other hospital measurement was done by an enzymatic creatinine p-aminophenazone method (interassay coefficient of variation, 1.2%-2.2%). Creatinine clearance was calculated according the Cockcroft- Gault formula. 14 Serum lipid measurements were performed by routine methods in both participating clinics. All markers were measured in a blinded fashion. STATISTICAL ANALYSIS Median levels of NT-proBNP were calculated according to levels of various sociodemographic characteristics, various cardiovascular risk factors, and levels of ECG findings. Associations of these factors with the NT-proBNP distribution were tested for statistical significance by the nonparametric Kruskal- Wallis test. A (partial) Spearman rank correlation coefficient between NT-proBNP, CRP, and CrCl was calculated after adjustment for age and sex. The relation of NT-proBNP, CRP, and CrCl levels with CVD events during follow-up was assessed by the Kaplan-Meier method. The Cox proportional hazards model was used to assess the independent association of NT-proBNP distribution with the risk of secondary CVD events. Besides a model adjusting for age and sex, the following potential confounders were considered in multivariable analyses: age, sex, body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]), smoking status, duration of school education, family status, history of MI, history of hypertension, history of diabetes mellitus, severity of CHD, intake of -blockers, intake of angiotensin-converting enzyme inhibitors, intake of diuretics, intake of lipid-lowering drugs, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, atrial flutter or fibrillation, left ventricular hypertrophy, anterior infarction location, 2456
3 posterior infarction location, and hospital site. To avoid overadjustment, the latter covariates were added only if they were significant predictors of a secondary event at an level of.10 or if their inclusion changed the parameter estimates for the main variables (NT-proBNP) by more than 10%. To compare their prognostic value with that of NTproBNP, CRP and CrCl levels were included instead of NTproBNP in additional analyses in the adjusted model (model 2), and, finally, NT-proBNP, CRP, and CrCl categories were included simultaneously (model 3). Finally, hazard ratios (HRs) were additionally adjusted for LVF (no or only little impairment, modest or severe impairment) (model 4). A receiver operating curve was constructed after adjustment for covariates, and the area under the curve with its 95% confidence interval (CI) was calculated. In addition, Somers D, a measure of association that provides a rank correlation between predicted and observed probabilities, was calculated for the various models. Somers D ranges between 1 and 1; 0 reflects no association at all. All statistical procedures were carried out with the SAS statistical software package (release 8.2 [1999]; SAS Institute Inc, Cary, NC ). RESULTS Overall, 1206 patients with a diagnosis of CHD within the past 3 months were included at baseline during the inhospital rehabilitation program. Four-year follow-up information was complete for 1051 patients (87.2%). Table 1 gives the distribution (median) of NTproBNP values according to various sociodemographic factors, cardiovascular risk factors, and ECG findings. Women and patients in the older age groups had statistically significantly higher NT-proBNP values, as did those with a BMI less than 25, patients with a history of diabetes, MI, and hypertension, those with a high angiography score, those who underwent CABG, and those with impaired LVF. As determined from 12-lead routine ECG, subjects with atrial flutter or fibrillation, signs of left ventricular hypertrophy, ECG signs of anterior infarction location and, to a lesser degree, ECG signs of posterior infarction location also had higher NT-proBNP serum concentrations compared with patients without these findings. Spearman rank correlation coefficient (r) was r=0.22 (P) between NT-proBNP and CRP and r= 0.24 (P) between NT-proBNP and CrCl. C-reactive protein and CrCl were not correlated with each other in a statistically significant way. During follow-up (mean [SD], 48.7 [15.9] months) 95 patients (9.0%) experienced a secondary CVD event. Thirty patients (2.9%) died from CVD, 35 patients (3.3%) had a nonfatal MI, and in 30 patients (2.9%), a stroke was diagnosed. Of patients in the top quartile of the NT-proBNP distribution, 16.5% experienced an event compared with 4.5%, 4.7%, and 9.1% in the first, second, and third quartile, respectively (P) (Figure). Of patients in the top quartile of the CRP distribution,12.6% experienced an event compared with 7.6%, 7.2%, and 8.7% in the first, second, and third quartile, respectively (P=.09). Of patients with a CrCl lower than 60 ml/min,13.6% experienced an event compared with 6.7% and 11.7% in the categories of 90 ml/min or higher and 60 to lower than 90 ml/min, respectively (P=.002). Table 1. N-Terminal Pro B-Natriuretic Peptide (NT-proBNP) Distribution According to Various Variables Variable No. of Patients NT-proBNP Distribution Median P Value* Sociodemographic Characteristics and Cardiovascular Risk Factors All (IQR, ) Sex Female Male Age, y School education, y Family status Married Other BMI Smoking status Never Former Current History of diabetes Yes No History of MI Yes No History of hypertension Yes No Angiographic score, No. of affected vessels 0/ (continued) Table 2 gives the results of multivariable analysis. Compared with patients in the bottom quartile of the NTproBNP distribution at baseline, patients in the top quartile had an HR of 3.34 (95% CI, ) for a CVD event during follow-up after adjustment for multiple covariates (P for trend, ). The respective HR for CRP was 1.76 (95% CI, ) (P for trend,.06). Compared with patients with a CrCl of 90 ml/min or higher at baseline, patients with a CrCl lower than 60 ml/min had an HR of 2.39 (95% CI, ) (P for trend,.002) after adjustment for multiple covariates. If all 3 markers were considered simultaneously and adjustment was done for potential confounders, NTproBNP level showed by far the strongest association with secondary CVD events. Results were similar if all 3 markers were included as continuous variables. If the final model was controlled for LVF, the HR decreased; however, NTproBNP values were still strong predictors of CVD events. 2457
4 Table 1. N-Terminal Pro B-Natriuretic Peptide (NT-proBNP) Distribution According to Various Variables (cont) Variable No. of Patients Finally, in Table 3 we quantified the incremental contribution of all 3 markers to risk prediction in the presence of classic risk factors. According to receiver operating curve analyses, the addition of NT-proBNP to the basic model improved the predictive accuracy of the model (area under the curve from 0.69 to 0.71) more than inclusion of CRP and CrCl; it did not improve further if all 3 variables were included simultaneously. COMMENT NT-proBNP Distribution Median P Value* Sociodemographic Characteristics and Cardiovascular Risk Factors Initial management of CHD Conservative PCI CABG LVF, degree of impairment No/only little Modest/severe Unknown Electrocardiographic Characteristics Sinus tachycardia Yes No Atrial flutter or fibrillation Yes No Left ventricular hypertrophy Yes No Anterior infarction location Yes No Posterior infarction location Yes No Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CABG, coronary artery bypass grafting; CHD, coronary heart disease; IQR, interquartile range; LVF, left ventricular function; PCI, percutaneous coronary intervention. *Kruskal-Wallis test. This prospective cohort study including 1051 patients aged 30 to 70 years with stable CHD at baseline demonstrates that increased NT-proBNP levels are strongly and independently associated with secondary CVD events and show a superior predictive utility when directly compared with markers of renal function and inflammation. Notably, the relationship persisted after adjustment for LVF. DETERMINANTS OF NT-proBNP PLASMA LEVELS B-type natriuretic peptide is a hormone that is produced and secreted mainly from ventricular cardiomyocytes as a response to an increased wall stress and has biological effects that counterbalance the effects of the reninangiotensin and the sympathetic nervous system. 7 Compared with BNP, NT-proBNP has a much longer half-life. Proportion of Event-Free Survivors Quartile NT-proBNP, ng/ml (Bottom Quartile) > > >1101 (Top Quartile) No. (%) of Patients 263 (25) 263 (25) 264 (25) 261 (25) Fatal and Nonfatal CVD Event During Follow-up, No. (Row %) 13 (4.5) 15 (4.7) 24 (9.1) 43 (16.5) Days It has been reported that in patients with acute MI, plasma levels of NT-proBNP could be divided in 2 phases: the first peak appearing days after the acute event as an acutephase response to the injured tissue 5,15 and the second peak appearing weeks thereafter as a result of impaired LVF. 5 All subjects in the present study were included weeks after the acute manifestation of CHD or CABG procedure and were in a clinically stable condition. Higher values were seen in women and in older subjects as described by others. 16 We found indicators of the severity of CHD (number of affected epicardial vessels) positively associated with NT-proBNP levels. Furthermore, patients with a history of MI or diabetes, various ECG findings such as atrial flutter or fibrillation, and signs of anterior or posterior infarction had higher NT-proBNP levels. The latter might be related to previous myocardial damage in response to ischemia, which most likely leads to elevated left ventricular diastolic filling pressure and in consequence, to the secretion of BNP. PROGNOSTIC VALUE OF NT-proBNP, CRP, AND CrCl P Value (Log-Rank Test) <.001 Figure. Distribution of N-terminal pro B-natriuretic peptide (NT-proBNP) in quartiles and proportion of patients (N=1051) without secondary fatal and nonfatal cardiovascular disease (CVD) events during follow-up. Despite adjusting for several potential confounding factors, the prognostic value of NT-proBNP concentrations was still statistically significant. It remained so even after adjustment for CRP and CrCl levels, both relevant markers associated with secondary cardiovascular events in patients with CHD. 2,3 A recent study in patients with acute coronary syndromes showed that NT-proBNP added prognostic information to measures of inflammation and renal impairment for subsequent mortality. 17 The fact that the prognostic information of NT-proBNP level was still evident if controlled for LVF at baseline suggests that additional prognostic information (besides the ones related to CHF or left ventricular hypertrophy) might play a role. This is supported by a recent population-based study including 3346 middle-aged subjects without CHF, in whom 2458
5 Table 2. N-Terminal Pro B-Natriuretic Peptide (NT-proBNP), Creatinine Clearance (CrCl), and CRP at Baseline and Association With Fatal and Nonfatal Cardiovascular Events During Follow-Up: Results of Multivariate Analyses* Measure Model 1 Model 2 Model 3 Model 4 NT-proBNP, ng/ml (bottom quartile) to ( ) 1.04 ( ) 1.04 ( ) 0.99 ( ) to ( ) 1.73 ( ) 1.64 ( ) 1.49 ( ) 1097 (top quartile) 3.33 ( ) 3.34 ( ) 2.89 ( ) 2.35 ( ) P for trend.007 CRP, mg/l 1.24 (bottom quartile) to ( ) 0.99 ( ) 0.90 ( ) 0.88 ( ) 3.51 to ( ) 1.08 ( ) 0.90 ( ) 0.87 ( ) 8.61 (top quartile) 1.60 ( ) 1.76 ( ) 1.35 ( ) 1.29 ( ) P value for trend CrCl, ml/min to ( ) 2.23 ( ) 1.75 ( ) 1.76 ( ) ( ) 2.39 ( ) 1.34 ( ) 1.39 ( ) P for trend Abbreviations: CI, confidence interval; CRP, C-reactive protein. *Data are given as hazard ratio (95% confidence interval) unless otherwise specified. Model 1 was adjusted for age and sex; model 2, for age, sex, smoking status, history of diabetes mellitus, initial management of coronary heart disease (conservative, percutaneous coronary intervention, and coronary artery bypass grafting), rehabilitation clinic, high-density lipoprotein cholesterol level, low-density lipoprotein cholesterol level, and treatment with lipid-lowering drugs (according to variable selection criteria); model 3 for variables in model 2 plus NT-proBNP, CRP, and CrCl simultaneously in 1 model; and model 4, for variables in model 3 plus left ventricular ejection fraction. plasma natriuretic peptide levels were of prognostic relevance for subsequent atrial fibrillation, stroke, and allcause mortality. 18 Notably, in the latter study the prognostic value was already evident at relatively low levels, which are usually not related to CHF. Our findings extend those of a recent report in which NT-proBNP in 1034 patients with CHD provided prognostic information on all-cause mortality independent of LVF. 11 Our data show that especially the risk for secondary CVD events is increased in patients with CHD and high NT-proBNP levels, and therefore NT-proBNP measurement may be useful for better risk stratification in patients with manifest CHD, suggesting a possible shift in emphasis from CRP level to natriuretic peptide levels in the future. The independence of NT-proBNP level from CRP level in relation to future cardiovascular events has also been suggested in a recent analysis including 570 patients with stable CHD. 12 In a substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial, only the inclusion of NT-proBNP improved the predictive ability by increasing the area under the curve, whereas various inflammatory markers did not, although they all showed a statistically significant association with a combined CVD end point. 19 Although CRP levels were associated tentatively with CVD events in our study, they did not significantly predict secondary CVD events. This finding is in accordance with recent observations by Danesh et al 20 and Campbell et al. 21 C-reactive protein level may be a better predictor in primary prevention and younger subjects. Whereas other studies reporting on the association between inflammatory markers and study end points represent highly selected populations from randomized clinical trials, 22,23 our study consisted of everyday patients from 1 large geographic area; for example, the Aggrastatto-Zocor (A-to-Z) Trial was conducted internationally, Table 3. Predictive Accuracy of Various Multivariate Models as Measured by an Increase in the Area Under the Receiver Operating Characteristic Curve (AUROC) and Somers D AUROC (95% CI) Somers D Model Adjusted for (1) Age, sex, smoking status, history of 0.69 ( ) 0.38 DM, initial management of CHD, rehabilitation clinic, HDL-C, LDL-C, and treatment with lipid-lowering drugs (2) Factors in (1) plus NT-proBNP 0.71 ( ) 0.42 (3) Factors in (1) plus CRP 0.69 ( ) 0.38 (4) Factors in (1) plus CrCl 0.70 ( ) 0.39 (5) All factors 0.71 ( ) 0.42 Abbreviations: CHD, coronary heart disease; CI, confidence interval; CrCl, creatinine clearance; CRP, C-reactive protein; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NT-proBNP, N-terminal pro B-natriuretic peptide. and subjects originated from over 40 different countries and had a special risk profile at baseline (mean CRP level, 20 mg/l; current smokers, approximately 40%). 23 B-type natriuretic peptide synthesis occurs in the necrotic as well as in the healthy myocardium. 24 Furthermore, BNP levels were shown to increase after exercise testing in patients with stable CHD, and levels reflected the size of the ischemic territory. 25 In 112 patients undergoing exercise testing, it was demonstrated that transient ischemia may result in an immediate rise in BNP level and, to a lesser degree, in NT-proBNP levels. 26 The elevation of NT-proBNP level in patients with CHD may be a result of a recurrent MI even if necrosis has not occurred 10,27 ; however, in the context of our study, it is difficult to separate ischemia from impaired LVF. 2459
6 STUDY LIMITATIONS The following limitations of our study should be considered. Although we had a large sample of patients with CHD, fatal CVD events were rare in this population. This is explained by the fact that case fatality is highest before hospitalization and during the early in-hospital phase. Furthermore, we could successfully follow up 87.2% of the patients; patients lost to follow-up were in general younger and had lower BMI, NT-proBNP, and CRP values. Not all patients were willing or able to participate in an in-hospital rehabilitation program. This may be a further reason for the slight underrepresentation of more severely ill patients in our sample, but on the other side, almost half of the patients had extensive (3 vessel) disease. Underrepresentation of severely ill patients does not adequately explain the positive findings between NT-proBNP serum concentration and CVD events but suggests that the true prognostic value of this marker may even be stronger than shown in our study. Information of global LVF was available for most patients; however, when this semiquantitative assessment was compared with quantitative ejection fraction (available for 471 patients) derived from left ventricular cineangiograms, excellent agreement was found (mean ejection fraction in semiquantitative global LVF categories: normal, 69.6%; mild depression, 54.9%; moderate depression, 44.1%; and severe depression, 30.0%). In conclusion, despite these limitations, our data are in support of an important prognostic value of NTproBNP among patients with known CHD and suggest that NT-proBNP level is a useful prognostic marker that provides complementary information to markers of inflammation and renal function and to other established risk determinants. Accepted for Publication: August 30, Correspondence: Wolfgang Koenig, MD, Department of Internal Medicine II Cardiology, University of Ulm Medical Center, Robert-Koch Str 8, D Ulm, Germany (wolfgang.koenig@uniklinik-ulm.de). Author Contributions: Dr Rothenbacher had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Rothenbacher and Brenner. Acquisition of data: Rothenbacher, Koenig, and Brenner. Analysis and interpretation of data: Rothenbacher and Koenig. Drafting of the manuscript: Rothenbacher. Critical revision of the manuscript for important intellectual content: Koenig and Brenner. Statistical analysis: Rothenbacher and Brenner. Obtained funding: Rothenbacher, Koenig, and Brenner. Administrative, technical, and material support: Rothenbacher and Brenner. Study supervision: Rothenbacher and Brenner. Financial Disclosure: None reported. Acknowledgment: We highly appreciate the excellent technical assistance of Gerlinde Trischler. We thank Roche, Mannheim (Germany), for providing the NTproBNP reagents. REFERENCES 1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Diseases Study. Lancet. 1997;349: Rosenson RS, Koenig W. High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. Curr Opin Cardiol. 2002;17: Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation. 2003;108: Smith MW, Espiner EQ, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neural endopeptidase. J Endocrinol. 2000;167: Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993; 88: de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001; 345: Hobbs FDR, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ. 2002; 324: Mukoyama M, Nakao K, Obata K, et al. Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun. 1991; 180: Morrow DA, de Lemos JA, Blazing MA, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA. 2005;294: Jernberg T, James S, Lindahl B, et al. Natriuretic peptides in unstable coronary artery disease. Eur Heart J. 2004;25: Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro- B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352: Schnabel R, Rupprecht HJ, Lackner KJ, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease. Eur Heart J. 2005;26: Ndrepepa G, Braun S, Niemöller K, et al. Prognostic value of N-terminal probrain natriuretic peptide in patients with chronic stable angina. Circulation. 2005; 112: Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16: Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci. 1982;389: Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40: James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. Circulation. 2003;108: Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350: Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006;114: Danesh J, Wheeler JC, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350: Campbell DJ, Woodward M, Chalmers JP, et al. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and rennin in subjects with cerebrovascular disease. Circulation. 2005;112: Harb TS, Zareba W, Moss AJ, et al. Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patients. Am J Cardiol. 2003; 91: Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114: Hama N, Itoh H, Shirakami G, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 1995;92: Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci. 1995;88: Sabatine MS, Morrow AD, delemos JA, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004; 44: Bibbins-Domingo K, Ansari M, Schiller NB, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation. 2003;108:
High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU
ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients
More informationLong-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease
Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner
More informationN-Terminal Pro B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease
The new england journal of medicine original article N-Terminal Pro B-Type Natriuretic Peptide and Long-Term Mortality in Stable Coronary Heart Disease Charlotte Kragelund, M.D., Bjørn Grønning, M.D.,
More informationThe Framingham Risk Score (FRS) is widely recommended
C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany Wolfgang Koenig, MD; Hannelore
More informationBNP as a Predictor of Cardiovascular Disease and All Cause Mortality. Dr. Thierry Le Jemtel
BNP as a Predictor of Cardiovascular Disease and All Cause Mortality Dr. Thierry Le Jemtel Outline Role of BNP and probnp as relevant biomarkers in cardiac conditions Role of BNP and probnp as relevant
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationImpact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease
Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,
More informationAcute Changes in Circulating Natriuretic Peptide Levels in Relation to Myocardial Ischemia
Journal of the American College of Cardiology Vol. 44, No. 10, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.07.057
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationB-Type Natriuretic Peptide and Ischemia in Patients With Stable Coronary Disease. Data From the Heart and Soul Study
B-Type Natriuretic Peptide and Ischemia in Patients With Stable Coronary Disease Data From the Heart and Soul Study Kirsten Bibbins-Domingo, PhD, MD; Maria Ansari, MD; Nelson B. Schiller, MD; Barry Massie,
More informationEarly risk stratification is essential in the management of
Cystatin C A Novel Predictor of Outcome in Suspected or Confirmed Non ST-Elevation Acute Coronary Syndrome Tomas Jernberg, MD, PhD; Bertil Lindahl, MD, PhD; Stefan James, MD, PhD; Anders Larsson, MD, PhD;
More informationSerum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease
Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease MAK Akanda 1, KN Choudhury 2, MZ Ali 1, MK Kabir 3, LN Begum 4, LA Sayami 1 1 National Institute of Cardiovascular
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized
More informationWinfried März, 1* Beate Tiran, 2 Ursula Seelhorst, 3 Britta Wellnitz, 3 Johann Bauersachs, 4 Bernhard R. Winkelmann, 5 and Bernhard O.
Clinical Chemistry 53:6 1075 1083 (2007) Proteomics and Protein Markers N-Terminal Pro-B-Type Natriuretic Peptide Predicts Total and Cardiovascular Mortality in Individuals with or without Stable Coronary
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationLow ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients
Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients N. Peltz-Sinvani, MD 1,4,R.Klempfner,MD 2,4, E. Ramaty, MD 1,4,B.A.Sela,PhD 3,4,I.Goldenberg,MD
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationSupplementary Online Content
Supplementary Online Content Li S, Chiuve SE, Flint A, et al. Better diet quality and decreased mortality among myocardial infarction survivors. JAMA Intern Med. Published online September 2, 2013. doi:10.1001/jamainternmed.2013.9768.
More informationJournal of the American College of Cardiology Vol. 41, No. 8, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 8, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(03)00168-2
More informationExercise treadmill testing is frequently used in clinical practice to
Preventive Cardiology FEATURE Case Report 55 Commentary 59 Exercise capacity on treadmill predicts future cardiac events Pamela N. Peterson, MD, MSPH 1-3 David J. Magid, MD, MPH 3 P. Michael Ho, MD, PhD
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationIntroduction. Key words: cardiac biomarkers; short-term mortality; perioperative risk; non-cardiac surgery; coronary artery disease
ISSN 2466-488X (Online) doi:10.5937/sjait1806117j Original work PREOPERATIVE HIGH-SENSITIVE TROPONIN T AND N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE IN PREDICTION OF SHORT-TERM MORTALITY AFTER NON-CARDIAC
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationTo estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome
Original Research Article To estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome Mohamed Yasar Arafath 1, K. Babu Raj 2* 1 First Year Post Graduate, 2
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationBiochemical risk assessment and invasive strategies for acute coronary syndromes without ST-segment elevation Riezebos, R.K.
UvA-DARE (Digital Academic Repository) Biochemical risk assessment and invasive strategies for acute coronary syndromes without ST-segment elevation Riezebos, R.K. Link to publication Citation for published
More informationORIGINAL INVESTIGATION. N-Terminal Pro B-Type Natriuretic Peptide as a Diagnostic Test for Ventricular Dysfunction in Patients With Coronary Disease
ORIGINAL INVESTIGATION N-Terminal Pro B-Type Natriuretic Peptide as a Diagnostic Test for Ventricular Dysfunction in Patients With Coronary Disease Data From the Heart and Soul Study David C. M. Corteville,
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationTiming of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism
7 Frederikus A. Klok Noortje van der Bijl Inge C.M. Mos Albert de Roos Lucia J. M. Kroft Menno V. Huisman Timing of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism Letter
More informationImportance of the third arterial graft in multiple arterial grafting strategies
Research Highlight Importance of the third arterial graft in multiple arterial grafting strategies David Glineur Department of Cardiovascular Surgery, Cliniques St Luc, Bouge and the Department of Cardiovascular
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationStudy of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri
Original Research Article Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri P. Sasikumar * Department of General Medicine, Govt.
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationSupplementary Online Content
Supplementary Online Content Nikolova AP, Hitzeman TC, Baum R, et al. Association of a novel diagnostic biomarker, the plasma cardiac bridging integrator 1 score, with heart failure with preserved ejection
More informationPredictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and NT-ProBNP Before Cardiac Surgery
Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and NT- Before Cardiac Surgery Sai Polineni, MPH; Devin M. Parker, MS; Shama S. Alam, PhD, MSc; Heather Thiessen-Philbrook, BMath, MMath;
More informationTroponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes
The new england journal of medicine Original Article Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes Brendan M. Everett, M.D., M.P.H., Maria Mori Brooks, Ph.D., Helen E.A. Vlachos,
More informationNew PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationRisk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium
Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from
More informationYOUNG ADULT MEN AND MIDDLEaged
BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,
More informationEffect of intravenous atropine on treadmill stress test results in patients with poor exercise capacity or chronotropic incompetence ABSTRACT
Effect of intravenous atropine on treadmill stress test results in patients with poor exercise capacity or chronotropic incompetence Samad Ghaffari, MD, Bahram Sohrabi, MD. ABSTRACT Objective: Exercise
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationPrognostic Value of Biomarkers During and After Non ST-Segment Elevation Acute Coronary Syndrome
Journal of the American College of Cardiology Vol. 54, No. 4, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.03.056
More informationAtrial natriuretic peptide (ANP) and brain natriuretic
Exertional Changes in Circulating Cardiac Natriuretic Peptides in Patients with Suggested Coronary Artery Disease Sébastien Bergeron, MD, Jacob E. Møller, MD, PhD, Kent R. Bailey, PhD, Horng H. Chen, MD,
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationSUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics
Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics
More informationEvaluation of Anthropometric Indices of Patients with Left Ventricle Dysfunction Fallowing First Acute Anterior Myocardial Infarction
Journal of Cardiovascular and Thoracic Research, 2012, 4(1), 11-15 doi: 10.5681/jcvtr.2012.003 http://jcvtr.tbzmed.ac.ir Evaluation of Anthropometric Indices of Patients with Left Ventricle Dysfunction
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationGlomerular Filtration Rate and N-Terminal Pro-Brain Natriuretic Peptide as Predictors of Cardiovascular Mortality in Vascular Patients
Journal of the American College of Cardiology Vol. 49, No. 22, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.02.047
More informationProf. Samir Morcos Rafla Alexandria Univ. Cardiology Dept.
Obesity as a risk factor for Atrial Fibrillation Prof. Samir Morcos Rafla Alexandria Univ. Cardiology Dept. CardioAlex 2010 smrafla@hotmail.com 1 Obesity has reached epidemic proportions in the United
More informationMethods Study population The design and objectives of CHS have been described elsewhere. 9 The CHS is a longitudinal study of 5,888 men
N-terminal pro-b-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study Kristen K. Patton, MD,* Nona Sotoodehnia, MD,* Christopher DeFilippi, MD, FACC, David
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationBiomarkers in the Assessment of Congestive Heart Failure
Biomarkers in the Assessment of Congestive Heart Failure Mid-Regional pro-adrenomedullin (MR-proADM) vs BNP & NT-proBNP as Prognosticator in Heart Failure Patients: Results of the BACH Multinational Trial
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationEffect of Short-term Maximal Exercise on BNP Plasma Levels in. Healthy Individuals
1 Effect of Short-term Maximal Exercise on BNP Plasma Levels in Healthy Individuals Jan Krupicka, MD, Tomas Janota, MD, Zdislava Kasalova, MD, Jaromir Hradec, MD 3rd Department of Internal Medicine, 1st
More informationAMINO-TERMINAL PRO-BRAIN NATRIURETIC PEPTID IN PREDICTION OF LEFT VENTRICULAR EJECTION FRACTION
& AMINO-TERMINAL PRO-BRAIN NATRIURETIC PEPTID IN PREDICTION OF LEFT VENTRICULAR EJECTION FRACTION Mugdim Bajrić¹, Fahir Baraković¹, Zumreta Kušljugić¹, Nermin Salkić¹, Elmir Jahić¹, Mensura Aščerić³*,
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More information*Christian M. Carlsen, 1 Mette Mouridsen, 1 Ahmad Sajadieh, 1 Lars Køber, 2 Olav W. Nielsen 1 ABSTRACT BACKGROUND
USE OF N-TERMINAL NATRIURETIC PEPTIDE IN A REAL- WORLD SETTING OF PATIENTS ADMITTED WITH ACUTE DYSPNOEA AND THE IMPLICATION FOR TRIAGING PATIENTS IN THE EMERGENCY DEPARTMENT *Christian M. Carlsen, 1 Mette
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationAcute coronary syndrome. Dr LM Murray Chemical Pathology Block SA
Acute coronary syndrome Dr LM Murray Chemical Pathology Block SA13-2014 Acute myocardial infarction (MI) MI is still the leading cause of death in many countries It is characterized by severe chest pain,
More informationHigh levels of N-terminal pro B-type natriuretic peptide are associated with ST resolution failure after reperfusion for acute myocardial infarction
Q J Med 2007; 100:211 216 doi:10.1093/qjmed/hcm013 High levels of N-terminal pro B-type natriuretic peptide are associated with ST resolution failure after reperfusion for acute myocardial infarction L.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to
More informationTable S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis
SUPPLEMENTARY MATERIAL TEXT Text S1. Multiple imputation TABLES Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis Table S2. List of drugs included as immunosuppressant
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationClinical Investigations
Clinical Investigations Predictors of 30-Day Readmission in Patients Hospitalized With Decompensated Heart Failure Address for correspondence: Gian M. Novaro, MD, Department of Cardiology, Cleveland Clinic
More informationPercutaneous Coronary Intervention versus Coronary Artery Bypass Graft in Acute Coronary Syndrome patients with Renal Dysfunction
www.nature.com/scientificreports Received: 26 June 2017 Accepted: 22 January 2018 Published: xx xx xxxx OPEN Percutaneous Coronary Intervention versus Coronary Artery Bypass Graft in Acute Coronary Syndrome
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationDUKECATHR Dataset Dictionary
DUKECATHR Dataset Dictionary Version of DUKECATH dataset for educational use that has been modified to be unsuitable for clinical research or publication (Created Date and Time: 28OCT16 14:35) Table of
More informationsphingotest vr-hgh Risk Prediction of Incident Cardiovascular Disease
sphingotest vr-hgh Risk Prediction of Incident Cardiovascular Disease Human Growth Hormone as Vascular Risk Biomarker sphingotec offers the vascular risk human Growth Hormone biomarker (vr-hgh) for the
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationProduct: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1
Date: 02 April 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Omecamtiv mecarbil injection Name of Active Ingredient: Omecamtiv mecarbil (AMG 423) Title of Study: A double-blind,
More information4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
More informationUndetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung, MD, PhD; Magnus Johansson, MD, PhD; Martin Holzmann,
More informationNIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2014 June 24.
NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2013 June 24; 173(12): 1150 1151. doi:10.1001/jamainternmed.2013.910. SSRI Use, Depression and Long-Term Outcomes
More informationQuality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationNT-proBNP A New Test for Diagnosis, Prognosis and Management of Congestive Heart Failure
Reference Section NT-proBNP A New Test for Diagnosis, Prognosis and Management of Congestive Heart Failure a report by Drs Rahul Sakhuja and James L Januzzi Cardiology Division and Department of Medicine,
More informationLDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC
Am J Cardiol (2004);94:729-32 Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors M. Y. Desai, et al. Ciccarone Preventive
More informationBiomarkers in risk prediction of heart and kidney disease
Biomarkers in risk prediction of heart and kidney disease Winfried März Medizinische Universität Graz, Medizinische Klinik V Medizinische Fakultät Mannheim, Universität Heidelberg, Synlab Akademie, Mannheim
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More information